A network meta-analysis of safety and efficacy of sodium-glucose cotransporter 2 inhibitors in heart failure patients
Empagliflozin was associated with the lowest risk of both cardiovascular mortality and serious side effects. While all SGLT2 inhibitors reduced the likelihood of hospitalizations for HF, canagliflozin did not show a significant benefit in this area. There were no significant differences between the SGLT2 inhibitors in terms of all-cause mortality, MI, stroke, or side effects leading to treatment discontinuation.
Authors
- M. A. Ibraheim
- Shadi Abuhashem
- Zinab Alatawi (ORCID: https://orcid.org/0000-0002-8963-8398)
- Leo Tom
- Mohammed Aramin
- Ashraf Mohammed Alhazmi
- Ashanti Hameed
- Kosar Doraghi
- Mohamed Amer Alshahrani
Institutions
- Nitte University (IN)
- University of Khartoum (SD)
- Al-Quds University (PS)
- King Fahd Medical City (SA)
- Centinela Hospital Medical Center (US)
- University of Belize (BZ)
- Armed Forces Hospital (SA)
- North West Armed Forces Hospital (SA)
- University of Tabuk (SA)
Publication Details
- Journal
- Annals of Medicine and Surgery
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1097/ms9.0000000000004669
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00